Research Reports

Key takeaways

SAB meeting with leading ophthalmology experts to review urcosimod Phase 2 data and guide upcoming clinical program during ASCRS in Washington, DC.

Dr. Pedram Hamrah presents urcosimod Phase 2 efficacy and safety results in Ocular Surface Disease II session on April 11, 2026.

Plans to initiate next clinical trial of urcosimod for NCP in first half of 2026.

Urcosimod received FDA Fast Track designation and is first IND for NCP treatment.

Positive Phase 2 data showed statistical significance in NCP pain reduction and prior dry eye endpoints.

Full analysis

OKYO Pharma's announcement highlights progress in urcosimod development for neuropathic corneal pain, a condition lacking FDA-approved therapies. The SAB meeting with corneal specialists during the prestigious ASCRS Annual Meeting enables strategic input on the next trial planned for H1 2026, building on positive Phase 2 results demonstrating pain reduction. Dr. Hamrah's presentation of efficacy and safety data from the 18-patient proof-of-concept study increases visibility among key opinion leaders. Urcosimod's Fast Track status and novel mechanism targeting ChemR23 receptor position it to address unmet needs in NCP and inflammatory eye diseases.

OKYO · OKYO Pharma Limited

Summary

Key takeaways

Full analysis